Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zicam Cough Melts is an over-the-counter antitussive medication indicated for the temporary relief of cough due to minor throat and bronchial irritation, such as those associated with the common cold or inhaled irritants. Unlike many other products under the Zicam brand that are marketed as homeopathic remedies, Zicam Cough Melts is a conventional pharmaceutical product containing the active ingredient dextromethorphan hydrobromide. Dextromethorphan is a synthetic d-isomer of the codeine analog levorphanol and acts centrally in the medulla oblongata to raise the cough threshold. Its primary mechanism of action involves agonism of the sigma-1 receptor and non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. The product is uniquely formulated as an orally disintegrating tablet (melt) to allow for rapid dissolution and administration without the need for water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zicam Cough Melts.